Inhalation; GasNCT06209112
Sevoflurane Wash in Method Using Conventional Flows Versus Low Flows of 0.5L
An observational study of Inhalation; Gas, run by Royal Hospital, Oman at 1 site in Oman.
Trial summary
The goal of this observational study is to to evaluate a technique of initiating Sevoflurane low-flow anesthesia which is simple, has a quick wash-in and minimises gas consumption without compromising the safety when compared to conventional method of attaining low-flow anesthesia using initial high flows. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Inhalation; Gas
- What is being tested?
- Sevoflurane
- How many people
- 48 participants
- Where
- 1 siteOman
- Study dates
- 30 Jan 2024to 1 Aug 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Forty-eight patients of either gender aged 18-65 years, with American Society of Anesthesiologists (ASA) physical status of 1-2, undergoing elective surgery with the expected duration more than 1 hour under general anaesthesia requiring endotracheal intubation will be included.
Who may be able to join
- American Society of Anesthesiologists (ASA) physical status 1 and 2
- elective surgery with the expected duration more than 1 hour under general anaesthesia requiring endotracheal intubation
Who cannot join
- Pregnant women
- smokers
- patients with a body mass index (BMI) ≥30 kg/m2
- cardiac/pulmonary/renal or liver impairments
- upper or lower respiratory infections within the past 6 weeks and anticipated difficult airway will be excluded.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Feasibility and Safety of an Over-pressure wash-in Method Using Fresh Gas Flow 0.5 L and Sevoflurane 8% During Initiation of Low-flow Anaesthesia: a Prospective, Randomised, Description Study
The goal of this observational study is to to evaluate a technique of initiating Sevoflurane low-flow anesthesia which is simple, has a quick wash-in and minimises gas consumption without compromising the safety when compared to conventional method of attaining low-flow anesthesia using initial high flows.
Participants will explained about the procedure of induction of general anesthesia using either one of the above two methods and written consent will be obtained prior to inclusion in the study.
Read the detailed description
After obtaining the approval from the Institutional Ethics Committee of The Royal Hospital, Muscat, we will register this prospective, randomised, descriptive study in an appropriate online clinical trial registry. A written informed consent will be obtained from all the patients. Forty-eight patients of either gender aged 18-65 years, with American Society of Anesthesiologists (ASA) physical status of 1-2, undergoing elective surgery with the expected duration more than 1 hour under general anaesthesia requiring endotracheal intubation will be included. Pregnant women, smokers, patients with a body mass index (BMI) ≥30 kg/m2, cardiac/pulmonary/renal or liver impairments, upper or lower respiratory infections within the past 6 weeks and anticipated difficult airway will be excluded.
Age, gender, height and weight of the patients will be recorded. All the patients will follow the standard fasting requirements and receive no sedative premedication. They will be randomised before entering the operating room into one of the two groups, 'conventional group' (Group C) and 'over-pressure group' (Group OP), using block randomisation technique with varying block sizes. An appropriate intravenous cannula will be secured in the operating room and Ringer's Lactate 500 ml will be started. The patients will receive standard anaesthetic care and intra-operative monitoring with electrocardiogram, pulse oximeter (SpO2), non-invasive blood pressure (NIBP) and capnography. Anaesthesia workstation (GE Healthcare, Madison, WI, USA) which has an integrated anaesthetic gas analyser, displays age-adjusted MAC according to the internal algorithm and returns sampled gas to the breathing system will be used in this study. The breathing system will consist of a 2 litres reservoir bag, disposable breathing circuit, heat-moisture exchanger and standard circle system with Sodalime as the CO2 absorbent. The workstation will be tested to ensure no leak in the system and vapourisers are calibrated.
Ideal Body Weight (IBW) of the patient will be calculated based on the following formula: IBW (kg)=50 + 0.91 (height in cm - 152.4) for Men and 45.5 + 0.91 (height in cm - 152.4) for Women. The ventilator will be preset in Pressure Control-Volume Guarantee (PCV-VG) mode with a tidal volume of 8 ml/kg of IBW, respiratory rate=14 breaths/min, positive end-expiratory pressure (PEEP)=5 cmH2O and an inspiratory:expiratory ratio of 1:2. The set minute volume will be noted. The alarm for end-tidal Sevoflurane (FES) will be set at 2% to alert the clinician.
Heart rate (HR), blood pressure (BP) and peripheral oxygen saturation will be recorded before induction of anaesthesia, every minute until 5 min after induction and every 5 min intervals thereafter. The FGF will be set at 6 L/min with 100% O2 during pre-oxygenation and manual ventilation. Following pre-oxygenation for 3 min, general anaesthesia will be induced with intravenous Fentanyl 2 μg/kg followed by Propofol 2 mg/kg administered over 30 seconds and Rocuronium 1 mg/kg for neuromuscular blockade. Lungs will be ventilated manually and propofol 20 mg every minute will be administered until tracheal intubation. Tracheal intubation with an appropriate size endotracheal tube (ETT) will be performed 90 seconds later, the cuff inflated to 25-30 cmH2O using a cuff-pressure monitor device and ETT secured with an adhesive tape. The correct ETT position will be confirmed by auscultation and square-wave capnography. FGF will be paused during intubation and restarted after inflating the ETT cuff. The FGF hereafter will consist of O2 and Air with a set FIO2=0.6. FGF and Sevoflurane vapouriser dial (FVS) will be set as per the group allocation and mechanical ventilation will begin. The time of opening of vapouriser will be considered Tzero.
Following will be the steps during wash-in for achieving LFA:
The 'conventional' group (Group C): FGF will be set to 6 L/min and the FVS 3% at Tzero. The FGFwill be reduced to 0.5 L/min upon reaching FAS 2%. Hereafter, the FVS will be set to 4% andmaintained till 15 min (T15) from Tzero.
The 'over-pressure' group (Group OP): FGF will be set to 0.5 L/min and FVS 8% at Tzero. Subsequently, the FVS will be set to 4% upon reaching FAS 2% and maintained till 15 min (T15) from Tzero.
The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% target concentration (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
Consumption of gases (Oxygen, Air and Sevoflurane) from the beginning until T15 will be retrieved. Any reduction in mean BP >20% from the baseline will be treated with intravenous Ephedrine 12 mg bolus and consumption of Ephedrine will be noted. Expired minute volume (MVE) at Ttarget and T15 will be noted. The study period will end at T15 in both the groups. Painting the surgical parts and draping will be permitted during the study period. Care will be taken to avoid any activity which risks ETT disconnection during the study period. Subsequent management of anaesthesia will be left to the discretion of the attending Anaesthesiologist.
For both the groups, 'stability of Sevoflurane concentration', defined as FAS in the target range of 1.6-2.4% during the time interval from Ttarget till T15 will be assessed. The investigator will be allowed during this period to increase or decrease if needed the vapouriser dial by 1% at a time every 2 min to keep the FES in the target range. The number of times the vapouriser dial is adjusted will be noted. The system will be considered 'stable' if the FAS is maintained in the target range without the need for dial adjustment and 'unstable' if vapouriser dial adjustment is needed at any time during this period. Delivery of Oxygen will be monitored to ensure at least 300 ml/min and delivered FIO2 at least 0.3 at all time. The investigator will be allowed to increase if needed the set FiO2 by 0.1 at a time every 2 min to keep the delivered FIO2>0.3. The number of times the set FIO2 is adjusted will be noted. End-tidal carbon dioxide (ETCO2) will be maintained <40.
For both the groups, 'stability of Sevoflurane concentration', defined as FAS in the target range of 1.6- 2.4% during the time interval from Ttarget till T15 will be assessed. The investigator will be allowed during this period to increase or decrease if needed the vapouriser dial by 1% at a time every 2 min to keep the FAS in the target range. The number of times the vapouriser dial is adjusted will be noted.
The system will be considered 'stable' if the FAS is maintained in the target range without the need for dial adjustment and 'unstable' if vapouriser dial adjustment is needed at any time during this period.
Delivery of Oxygen will be monitored to ensure at least 300 ml/min and delivered FIO2 at least 0.3 at all time. The investigator will be allowed to increase if needed the set FIO2 by 0.1 at a time every 2 min to keep the delivered FIO2>0.3. The number of times the set FIO2 is adjusted will be noted. Endtidal carbon dioxide (ETCO2) will be maintained between 30 and 40. The aim of the study is to assess during the wash-in phase of LFA the feasibility of the method, stability of the system and consumption of gases. The primary outcome will be the time required to achieve FAS 2%. Secondary outcomes will be the stability of the system assessed by the number of times vapouriser dial and the set FIO2 adjusted, consumption of gases and of ephedrine.
Statistical analysis Sample size is calculated based on a previous study8 which showed the 1-1-8 wash-in scheme with FGF=2L (O2 1 L + Air 1 L) and Sevoflurane dial at 8% yielded an FAS of 2% at 2 ± 0.5 min. Hence, we assume that with our wash-in technique using FGF=0.5 L (O2 + Air) and FVS 8% the time needed to reach FAS=2% will be around 8 min. To detect a difference of 2 min (25%) with standard deviation (SD) of 2 using an alpha level of 0.05 and a power of 0.90 the sample size needed is 22 per group. For a possible 10% dropouts, it is decided to include 24 patients per group.
Statistical analysis will be carried out using an appropriate statistical software. Data will be presented as mean ± SD or median (range). Intergroup differences will be assessed for significance using Student's t, Kruskal-Wallis, chi-squared or Fisher exact tests, as appropriate. P < 0.05 will be considered statistically significant.
- Conditions
- Inhalation; Gas
- Being tested
- Sevoflurane
- Medical subject headings
- Respiratory Aspiration, Mucopolysaccharidosis IV
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SevofluraneDrug
The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
| Study group | Role | What they receive |
|---|---|---|
| Conventional group' (Group C) | The 'conventional' group (Group C): FGF will be set to 6 L/min and the FVS 3% at Tzero. The FGF will be reduced to 0.5 L/min upon reaching FAS 2%. Hereafter, the FVS will be set to 4% and maintained till 15 min (T15) from Tzero. Receives: Drug: Sevoflurane | |
| Over-pressure group' (Group OP) | The 'over-pressure' group (Group OP): FGF will be set to 0.5 L/min and FVS 8% at Tzero.
Subsequently, the FVS will be set to 4% upon reaching FAS 2% and maintained till 15 min (T15) from Tzero. Receives: Drug: Sevoflurane |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time required to achieve alveolar concentration of sevoflurane at 2%
The primary outcome will be the time required to achieve FAS 2%.
Measured: 15 minutes
Secondary outcomes (1)
To know the stability of the circle system
Secondary outcomes will be the stability of the system assessed by the number of times vapouriser dial adjusted and number of times the set FIO2 adjusted, consumption of ephedrine and consumption of gases.
Measured: 15 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jan 2024
- Study start30 Jan 2024
- Primary completion1 Aug 2024
- Study completion1 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Inhalation; GasStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Royal Hospital, Oman
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Harihar V Hegde, Royal Hospital, Oman
- Investigators
- Harihar V Hegde, MD, Principal investigator, The Royal Hospital, Oman
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06209112
- Sponsor's protocol ID
- MoH/CSR/23/27624
- Status last verified
- Aug 2024
- First submitted
- 6 Jan 2024
- Last updated
- 27 Aug 2024
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Since the study group subjects are ASA physical status 1 and 2 patients, the patient data will not be valuable to any other researchers
Publications
Baum JA. Low-flow anesthesia: theory, practice, technical preconditions, advantages, and foreign gas accumulation. J Anesth. 1999;13(3):166-74. doi: 10.1007/s005400050050. No abstract available.
PubMed 14530937Brattwall M, Warren-Stomberg M, Hesselvik F, Jakobsson J. Brief review: theory and practice of minimal fresh gas flow anesthesia. Can J Anaesth. 2012 Aug;59(8):785-97. doi: 10.1007/s12630-012-9736-2. Epub 2012 Jun 1.
PubMed 22653840Tribuddharat S, Sathitkarnmanee T, Vattanasiriporn N, Thananun M, Nonlhaopol D, Somdee W. 1-1-8 one-step sevoflurane wash-in scheme for low-flow anesthesia: simple, rapid, and predictable induction. BMC Anesthesiol. 2020 Jan 24;20(1):23. doi: 10.1186/s12871-020-0940-2.
PubMed 31980020Horwitz M, Jakobsson JG. Desflurane and sevoflurane use during low- and minimal-flow anesthesia at fixed vaporizer settings. Minerva Anestesiol. 2016 Feb;82(2):180-5. Epub 2015 Jul 22.
PubMed 26198766Jakobsson P, Lindgren M, Jakobsson JG. Wash-in and wash-out of sevoflurane in a test-lung model: A comparison between Aisys and FLOW-i. F1000Res. 2017 Mar 29;6:389. doi: 10.12688/f1000research.11255.2. eCollection 2017.
PubMed 28529707Upadya M, Saneesh PJ. Low-flow anaesthesia - underused mode towards "sustainable anaesthesia". Indian J Anaesth. 2018 Mar;62(3):166-172. doi: 10.4103/ija.IJA_413_17.
PubMed 29643549
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility and Safety of an Over-pressure wash-in Method Using Fresh Gas Flow 0.5 L and Sevoflurane 8% During Initiation of Low-flow Anaesthesia: a Prospective, Randomised, Description Study
- ClinicalTrials.gov ID
- NCT06209112
- Acronym / sponsor ID
- MoH/CSR/23/27624
- Conditions
- Inhalation; Gas
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Royal Hospital, OmanOther government
- Study start
- 30 Jan 2024 (actual)
- Primary completion
- 1 Aug 2024 (actual)
- Study completion
- 1 Aug 2024 (actual)
- First posted
- 17 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to to evaluate a technique of initiating Sevoflurane low-flow anesthesia which is simple, has a quick wash-in and minimises gas consumption without compromising the safety when compared to conventional method of attaining low-flow anesthesia using initial high flows.
Participants will explained about the procedure of induction of general anesthesia using either one of the above two methods and written consent will be obtained prior to inclusion in the study.
Detailed description
After obtaining the approval from the Institutional Ethics Committee of The Royal Hospital, Muscat, we will register this prospective, randomised, descriptive study in an appropriate online clinical trial registry. A written informed consent will be obtained from all the patients. Forty-eight patients of either gender aged 18-65 years, with American Society of Anesthesiologists (ASA) physical status of 1-2, undergoing elective surgery with the expected duration more than 1 hour under general anaesthesia requiring endotracheal intubation will be included. Pregnant women, smokers, patients with a body mass index (BMI) ≥30 kg/m2, cardiac/pulmonary/renal or liver impairments, upper or lower respiratory infections within the past 6 weeks and anticipated difficult airway will be excluded.
Age, gender, height and weight of the patients will be recorded. All the patients will follow the standard fasting requirements and receive no sedative premedication. They will be randomised before entering the operating room into one of the two groups, 'conventional group' (Group C) and 'over-pressure group' (Group OP), using block randomisation technique with varying block sizes. An appropriate intravenous cannula will be secured in the operating room and Ringer's Lactate 500 ml will be started. The patients will receive standard anaesthetic care and intra-operative monitoring with electrocardiogram, pulse oximeter (SpO2), non-invasive blood pressure (NIBP) and capnography. Anaesthesia workstation (GE Healthcare, Madison, WI, USA) which has an integrated anaesthetic gas analyser, displays age-adjusted MAC according to the internal algorithm and returns sampled gas to the breathing system will be used in this study. The breathing system will consist of a 2 litres reservoir bag, disposable breathing circuit, heat-moisture exchanger and standard circle system with Sodalime as the CO2 absorbent. The workstation will be tested to ensure no leak in the system and vapourisers are calibrated.
Ideal Body Weight (IBW) of the patient will be calculated based on the following formula: IBW (kg)=50 + 0.91 (height in cm - 152.4) for Men and 45.5 + 0.91 (height in cm - 152.4) for Women. The ventilator will be preset in Pressure Control-Volume Guarantee (PCV-VG) mode with a tidal volume of 8 ml/kg of IBW, respiratory rate=14 breaths/min, positive end-expiratory pressure (PEEP)=5 cmH2O and an inspiratory:expiratory ratio of 1:2. The set minute volume will be noted. The alarm for end-tidal Sevoflurane (FES) will be set at 2% to alert the clinician.
Heart rate (HR), blood pressure (BP) and peripheral oxygen saturation will be recorded before induction of anaesthesia, every minute until 5 min after induction and every 5 min intervals thereafter. The FGF will be set at 6 L/min with 100% O2 during pre-oxygenation and manual ventilation. Following pre-oxygenation for 3 min, general anaesthesia will be induced with intravenous Fentanyl 2 μg/kg followed by Propofol 2 mg/kg administered over 30 seconds and Rocuronium 1 mg/kg for neuromuscular blockade. Lungs will be ventilated manually and propofol 20 mg every minute will be administered until tracheal intubation. Tracheal intubation with an appropriate size endotracheal tube (ETT) will be performed 90 seconds later, the cuff inflated to 25-30 cmH2O using a cuff-pressure monitor device and ETT secured with an adhesive tape. The correct ETT position will be confirmed by auscultation and square-wave capnography. FGF will be paused during intubation and restarted after inflating the ETT cuff. The FGF hereafter will consist of O2 and Air with a set FIO2=0.6. FGF and Sevoflurane vapouriser dial (FVS) will be set as per the group allocation and mechanical ventilation will begin. The time of opening of vapouriser will be considered Tzero.
Following will be the steps during wash-in for achieving LFA:
The 'conventional' group (Group C): FGF will be set to 6 L/min and the FVS 3% at Tzero. The FGFwill be reduced to 0.5 L/min upon reaching FAS 2%. Hereafter, the FVS will be set to 4% andmaintained till 15 min (T15) from Tzero.
The 'over-pressure' group (Group OP): FGF will be set to 0.5 L/min and FVS 8% at Tzero. Subsequently, the FVS will be set to 4% upon reaching FAS 2% and maintained till 15 min (T15) from Tzero.
The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% target concentration (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
Consumption of gases (Oxygen, Air and Sevoflurane) from the beginning until T15 will be retrieved. Any reduction in mean BP >20% from the baseline will be treated with intravenous Ephedrine 12 mg bolus and consumption of Ephedrine will be noted. Expired minute volume (MVE) at Ttarget and T15 will be noted. The study period will end at T15 in both the groups. Painting the surgical parts and draping will be permitted during the study period. Care will be taken to avoid any activity which risks ETT disconnection during the study period. Subsequent management of anaesthesia will be left to the discretion of the attending Anaesthesiologist.
For both the groups, 'stability of Sevoflurane concentration', defined as FAS in the target range of 1.6-2.4% during the time interval from Ttarget till T15 will be assessed. The investigator will be allowed during this period to increase or decrease if needed the vapouriser dial by 1% at a time every 2 min to keep the FES in the target range. The number of times the vapouriser dial is adjusted will be noted. The system will be considered 'stable' if the FAS is maintained in the target range without the need for dial adjustment and 'unstable' if vapouriser dial adjustment is needed at any time during this period. Delivery of Oxygen will be monitored to ensure at least 300 ml/min and delivered FIO2 at least 0.3 at all time. The investigator will be allowed to increase if needed the set FiO2 by 0.1 at a time every 2 min to keep the delivered FIO2>0.3. The number of times the set FIO2 is adjusted will be noted. End-tidal carbon dioxide (ETCO2) will be maintained <40.
For both the groups, 'stability of Sevoflurane concentration', defined as FAS in the target range of 1.6- 2.4% during the time interval from Ttarget till T15 will be assessed. The investigator will be allowed during this period to increase or decrease if needed the vapouriser dial by 1% at a time every 2 min to keep the FAS in the target range. The number of times the vapouriser dial is adjusted will be noted.
The system will be considered 'stable' if the FAS is maintained in the target range without the need for dial adjustment and 'unstable' if vapouriser dial adjustment is needed at any time during this period.
Delivery of Oxygen will be monitored to ensure at least 300 ml/min and delivered FIO2 at least 0.3 at all time. The investigator will be allowed to increase if needed the set FIO2 by 0.1 at a time every 2 min to keep the delivered FIO2>0.3. The number of times the set FIO2 is adjusted will be noted. Endtidal carbon dioxide (ETCO2) will be maintained between 30 and 40. The aim of the study is to assess during the wash-in phase of LFA the feasibility of the method, stability of the system and consumption of gases. The primary outcome will be the time required to achieve FAS 2%. Secondary outcomes will be the stability of the system assessed by the number of times vapouriser dial and the set FIO2 adjusted, consumption of gases and of ephedrine.
Statistical analysis Sample size is calculated based on a previous study8 which showed the 1-1-8 wash-in scheme with FGF=2L (O2 1 L + Air 1 L) and Sevoflurane dial at 8% yielded an FAS of 2% at 2 ± 0.5 min. Hence, we assume that with our wash-in technique using FGF=0.5 L (O2 + Air) and FVS 8% the time needed to reach FAS=2% will be around 8 min. To detect a difference of 2 min (25%) with standard deviation (SD) of 2 using an alpha level of 0.05 and a power of 0.90 the sample size needed is 22 per group. For a possible 10% dropouts, it is decided to include 24 patients per group.
Statistical analysis will be carried out using an appropriate statistical software. Data will be presented as mean ± SD or median (range). Intergroup differences will be assessed for significance using Student's t, Kruskal-Wallis, chi-squared or Fisher exact tests, as appropriate. P < 0.05 will be considered statistically significant.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Conventional group' (Group C) | – | Drug: SevofluraneThe 'conventional' group (Group C): FGF will be set to 6 L/min and the FVS 3% at Tzero. The FGF will be reduced to 0.5 L/min upon reaching FAS 2%. Hereafter, the FVS will be set to 4% and maintained till 15 min (T15) from Tzero. |
| Over-pressure group' (Group OP) | – | Drug: SevofluraneThe 'over-pressure' group (Group OP): FGF will be set to 0.5 L/min and FVS 8% at Tzero. Subsequently, the FVS will be set to 4% upon reaching FAS 2% and maintained till 15 min (T15) from Tzero. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Forty-eight patients of either gender aged 18-65 years, with American Society of Anesthesiologists (ASA) physical status of 1-2, undergoing elective surgery with the expected duration more than 1 hour under general anaesthesia requiring endotracheal intubation will be included.
Key inclusion criteria (2 listed)
- American Society of Anesthesiologists (ASA) physical status 1 and 2
- elective surgery with the expected duration more than 1 hour under general anaesthesia requiring endotracheal intubation
Key exclusion criteria (5 listed)
- Pregnant women
- smokers
- patients with a body mass index (BMI) ≥30 kg/m2
- cardiac/pulmonary/renal or liver impairments
- upper or lower respiratory infections within the past 6 weeks and anticipated difficult airway will be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SevofluraneThe time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15. | Drug | Conventional group' (Group C), Over-pressure group' (Group OP) |
Primary outcome
Time required to achieve alveolar concentration of sevoflurane at 2%
Time frame: 15 minutes
The primary outcome will be the time required to achieve FAS 2%.
1 secondary outcome
To know the stability of the circle system
Time frame: 15 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2024.
- Background: PubMed 14530937Baum JA. Low-flow anesthesia: theory, practice, technical preconditions, advantages, and foreign gas accumulation. J Anesth. 1999;13(3):166-74. doi: 10.1007/s005400050050. No abstract available.
- Background: PubMed 22653840Brattwall M, Warren-Stomberg M, Hesselvik F, Jakobsson J. Brief review: theory and practice of minimal fresh gas flow anesthesia. Can J Anaesth. 2012 Aug;59(8):785-97. doi: 10.1007/s12630-012-9736-2. Epub 2012 Jun 1.
- Background: PubMed 31980020Tribuddharat S, Sathitkarnmanee T, Vattanasiriporn N, Thananun M, Nonlhaopol D, Somdee W. 1-1-8 one-step sevoflurane wash-in scheme for low-flow anesthesia: simple, rapid, and predictable induction. BMC Anesthesiol. 2020 Jan 24;20(1):23. doi: 10.1186/s12871-020-0940-2.
- Background: PubMed 26198766Horwitz M, Jakobsson JG. Desflurane and sevoflurane use during low- and minimal-flow anesthesia at fixed vaporizer settings. Minerva Anestesiol. 2016 Feb;82(2):180-5. Epub 2015 Jul 22.
- Background: PubMed 28529707Jakobsson P, Lindgren M, Jakobsson JG. Wash-in and wash-out of sevoflurane in a test-lung model: A comparison between Aisys and FLOW-i. F1000Res. 2017 Mar 29;6:389. doi: 10.12688/f1000research.11255.2. eCollection 2017.
- Background: PubMed 29643549Upadya M, Saneesh PJ. Low-flow anaesthesia - underused mode towards "sustainable anaesthesia". Indian J Anaesth. 2018 Mar;62(3):166-172. doi: 10.4103/ija.IJA_413_17.
- Individual participant dataSharing planned: Undecided. Since the study group subjects are ASA physical status 1 and 2 patients, the patient data will not be valuable to any other researchers
Related trials for Inhalation; Gas
Not yet recruitingObservational study
Hyperoxemia and Oxygen Reserve Index During Neurointerventional Anesthesia
Hyperoxia, Hyperoxemia
Recruiting
Acapella vs Flutter Devices for Improving Breathing and Lung Function After Lobectomy
Lobotomy Syndrome
Not yet recruitingPhase 1/2
The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD
Chronic Obstructive Pulmonary Disease
Recruiting
Effect of Acute Hypoxia on RIght VEntRicular Function in Asthma.
Hypoxia, Altitude, Hypoxia
Recruiting
Effect of Acute Hypoxia on RIght VEntRicular Function in HAPE.
Altitude Hypoxia, Hypoxia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Harihar V Hegde, MD principal investigator
The Royal Hospital, Oman
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Inhalation; Gas, run by Royal Hospital, Oman at 1 site in Oman.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Oman. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time required to achieve alveolar concentration of sevoflurane at 2% (time frame: 15 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06209112, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2024.